Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 2.66 USD -2.21%
Market Cap: 783.8m USD
Have any thoughts about
Abcellera Biologics Inc?
Write Note

Intrinsic Value

ABCL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ABCL stock under the Base Case scenario is 1.92 USD. Compared to the current market price of 2.66 USD, Abcellera Biologics Inc is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ABCL Intrinsic Value
1.92 USD
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Abcellera Biologics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ABCL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ABCL?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Life Sciences Tools & Services Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Abcellera Biologics Inc

Provide an overview of the primary business activities
of Abcellera Biologics Inc.

What unique competitive advantages
does Abcellera Biologics Inc hold over its rivals?

What risks and challenges
does Abcellera Biologics Inc face in the near future?

Summarize the latest earnings call
of Abcellera Biologics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Abcellera Biologics Inc.

Provide P/S
for Abcellera Biologics Inc.

Provide P/E
for Abcellera Biologics Inc.

Provide P/OCF
for Abcellera Biologics Inc.

Provide P/FCFE
for Abcellera Biologics Inc.

Provide P/B
for Abcellera Biologics Inc.

Provide EV/S
for Abcellera Biologics Inc.

Provide EV/GP
for Abcellera Biologics Inc.

Provide EV/EBITDA
for Abcellera Biologics Inc.

Provide EV/EBIT
for Abcellera Biologics Inc.

Provide EV/OCF
for Abcellera Biologics Inc.

Provide EV/FCFF
for Abcellera Biologics Inc.

Provide EV/IC
for Abcellera Biologics Inc.

Show me price targets
for Abcellera Biologics Inc made by professional analysts.

What are the Revenue projections
for Abcellera Biologics Inc?

How accurate were the past Revenue estimates
for Abcellera Biologics Inc?

What are the Net Income projections
for Abcellera Biologics Inc?

How accurate were the past Net Income estimates
for Abcellera Biologics Inc?

What are the EPS projections
for Abcellera Biologics Inc?

How accurate were the past EPS estimates
for Abcellera Biologics Inc?

What are the EBIT projections
for Abcellera Biologics Inc?

How accurate were the past EBIT estimates
for Abcellera Biologics Inc?

Compare the revenue forecasts
for Abcellera Biologics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Abcellera Biologics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Abcellera Biologics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Abcellera Biologics Inc compared to its peers.

Compare the P/E ratios
of Abcellera Biologics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Abcellera Biologics Inc with its peers.

Analyze the financial leverage
of Abcellera Biologics Inc compared to its main competitors.

Show all profitability ratios
for Abcellera Biologics Inc.

Provide ROE
for Abcellera Biologics Inc.

Provide ROA
for Abcellera Biologics Inc.

Provide ROIC
for Abcellera Biologics Inc.

Provide ROCE
for Abcellera Biologics Inc.

Provide Gross Margin
for Abcellera Biologics Inc.

Provide Operating Margin
for Abcellera Biologics Inc.

Provide Net Margin
for Abcellera Biologics Inc.

Provide FCF Margin
for Abcellera Biologics Inc.

Show all solvency ratios
for Abcellera Biologics Inc.

Provide D/E Ratio
for Abcellera Biologics Inc.

Provide D/A Ratio
for Abcellera Biologics Inc.

Provide Interest Coverage Ratio
for Abcellera Biologics Inc.

Provide Altman Z-Score Ratio
for Abcellera Biologics Inc.

Provide Quick Ratio
for Abcellera Biologics Inc.

Provide Current Ratio
for Abcellera Biologics Inc.

Provide Cash Ratio
for Abcellera Biologics Inc.

What is the historical Revenue growth
over the last 5 years for Abcellera Biologics Inc?

What is the historical Net Income growth
over the last 5 years for Abcellera Biologics Inc?

What is the current Free Cash Flow
of Abcellera Biologics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Abcellera Biologics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Abcellera Biologics Inc

Current Assets 742.9m
Cash & Short-Term Investments 643.1m
Receivables 63.2m
Other Current Assets 36.5m
Non-Current Assets 649.9m
Long-Term Investments 84.1m
PP&E 331.3m
Intangibles 100.4m
Other Non-Current Assets 134.2m
Current Liabilities 79.6m
Accounts Payable 34.8m
Accrued Liabilities 11.1m
Other Current Liabilities 33.7m
Non-Current Liabilities 235.2m
Other Non-Current Liabilities 235.2m
Efficiency

Earnings Waterfall
Abcellera Biologics Inc

Revenue
33m USD
Operating Expenses
-341m USD
Operating Income
-308.1m USD
Other Expenses
132.3m USD
Net Income
-175.8m USD

Free Cash Flow Analysis
Abcellera Biologics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ABCL Profitability Score
Profitability Due Diligence

Abcellera Biologics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive 3-Year Average ROIC
Low 3-Year Average ROE
Negative 1-Year Revenue Growth
23/100
Profitability
Score

Abcellera Biologics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ABCL Solvency Score
Solvency Due Diligence

Abcellera Biologics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
64/100
Solvency
Score

Abcellera Biologics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABCL Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast ABCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABCL is 15.74 USD with a low forecast of 5.05 USD and a high forecast of 29.4 USD.

Lowest
Price Target
5.05 USD
90% Upside
Average
Price Target
15.74 USD
492% Upside
Highest
Price Target
29.4 USD
1 005% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ABCL?

Click here to dive deeper.

Dividends

Abcellera Biologics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ABCL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

ABCL News

Other Videos

Profile

Abcellera Biologics Inc Logo
Abcellera Biologics Inc

Country

Canada

Industry

Life Sciences Tools & Services

Market Cap

773.6m USD

Dividend Yield

0%

Description

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

Contact

BRITISH COLUMBIA
Vancouver
2215 Yukon Street
+16045599005.0
www.abcellera.com

IPO

2020-12-11

Employees

386

Officers

CEO, President & Chairperson
Dr. Carl L.G. Hansen Ph.D.
Chief Financial Officer
Mr. Andrew Booth M.B.A.
COO & Director
Dr. Veronique Lecault Ph.D.
Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer
Mr. Tryn T. Stimart Esq., J.D., M.Sc.
Senior Director of Finance & Accounting
Marcie Thiessen CPA, CGA
Chief Technology Officer
Dr. Ester Falconer Ph.D.
Show More
Head of Corporate Communications
Kathleen Reid B.A.
Director of Corporate Development
Graham Craig M.Sc.
Senior Vice President of Partnering
Mr. Murray McCutcheon Ph.D.
Chief Commercial Officer
Mr. Neil Aubuchon B.A., M.B.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ABCL stock?

The intrinsic value of one ABCL stock under the Base Case scenario is 1.92 USD.

Is ABCL stock undervalued or overvalued?

Compared to the current market price of 2.66 USD, Abcellera Biologics Inc is Overvalued by 28%.

Back to Top